We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

MERIDIAN BIOSCIENCE

Meridian Bioscience manufactures, markets, and distributes diagnostic test kits, purified reagents and biopharmaceuti... read more Featured Products: More products

Download Mobile App




Meridian Bioscience Launches Two New Master Mixes That Detect DNA and RNA in Crude Saliva Samples

By LabMedica International staff writers
Posted on 01 Feb 2022

Meridian Bioscience, Inc. More...

(Cincinnati, OH, USA) has launched two new master mixes that detect DNA and RNA in crude saliva samples.

These two new mixes, Lyo-Ready Direct DNA qPCR Saliva Mix and Lyo-Ready Direct RNA/DNA qPCR Saliva Mix can be used in liquid format or lyophilized. Both mixes accelerate the development of diagnostic assays and improve assay sensitivity using saliva samples with direct qPCR protocols. Saliva is a non-invasive clinical sample utilized for diagnostic testing across many diseases, including cancer, HIV, and respiratory diseases (e.g., flu, bronchiolitis, pneumonia, and COVID-19). Saliva is one of the easiest samples to collect and handle; however, PCR inhibitors naturally present in high concentrations in the sample create challenges in developing highly sensitive and reliable saliva-based assays.

Similar to the innovative portfolio of Air-Dryable sample-specific master mixes, Meridian's new Lyo-Ready saliva-specific master mixes are optimized for use on crudely processed saliva or sputum samples for enhanced assay sensitivity and flexible protocols. They are "ready-to-use," with no further optimization required aside from the addition of primers and probes. Additionally, these mixes are stable in a liquid format or can be lyophilized to create ambient temperature-stable assays for point-of-care applications.

"With the surge of COVID-19 infections caused by the Omicron variant along with a rapid increase of other respiratory infections, the need for direct saliva testing has never been greater," said Lourdes Weltzien, Ph.D., Executive Vice President - Life Science. "Direct RT-qPCR saliva assays offer fast and convenient sample analysis, improve logistics and reduce costs involved in sample handling and transport. We are pleased to be the first to offer a complete solution for anyone developing a saliva-based molecular assay, whether in liquid, lyophilized or air-dried format."

Related Links:
Meridian Bioscience, Inc.


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.